Her-2/neu overexpression is associated with thrombospondin-1-related angiogenesis and thrombospondin-1-unrelated lymphangiogenesis in breast cancer

Ming Chuan Hong; Cheng Yu Long; Yu Feng Tian; Ming Ping Wu

doi:10.1016/j.gmit.2013.07.001

Her-2/neu overexpression is associated with thrombospondin-1-related angiogenesis and thrombospondin-1-unrelated lymphangiogenesis in breast cancer

Ming Chuan Hong, Cheng Yu Long, Yu Feng Tian, Ming Ping Wu

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Introduction: Her-2/. neu overexpression is linked to poor prognosis and is a significant predictor of the response to trastuzumab (i.e., herceptin) therapy in breast cancer patients. Her-2/. neu promotes angiogenesis with thrombospondin-1 (TSP-1) as a mediator in breast cancer development and progression. However, the clinical quantitative evaluation of Her-2/. neu and specified localization of TSP-1 are currently lacking. Materials and methods: In this study, immunohistochemistry was performed to elucidate the invivo relationships between Her-2/. neu and TSP-1 expression, angiogenesis, and lymphangiogenesis in breast cancer. Based on immunohistochemical staining for anti-Her-2/. neu and related quantitative scoring of tumor cells, 28 individuals with high Her-2/. Neu expression (i.e., with a score of ≥2.0) were recruited into the study group. Another 28 individuals with low Her-2/. neu (i.e., with a score of

Original language	English
Pages (from-to)	114-121
Number of pages	8
Journal	Gynecology and Minimally Invasive Therapy
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/j.gmit.2013.07.001
Publication status	Published - Nov 2013

Keywords

Angiogenesis
Automated cellular imaging system
Breast cancer
Her-2/neu
Lymphangiogenesis
Thrombospondin-1
Tumor-stroma interaction

ASJC Scopus subject areas

Obstetrics and Gynaecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.gmit.2013.07.001

Cite this

@article{83cef356b82644e3bc309fb10c109a7e,

title = "Her-2/neu overexpression is associated with thrombospondin-1-related angiogenesis and thrombospondin-1-unrelated lymphangiogenesis in breast cancer",

abstract = "Introduction: Her-2/. neu overexpression is linked to poor prognosis and is a significant predictor of the response to trastuzumab (i.e., herceptin) therapy in breast cancer patients. Her-2/. neu promotes angiogenesis with thrombospondin-1 (TSP-1) as a mediator in breast cancer development and progression. However, the clinical quantitative evaluation of Her-2/. neu and specified localization of TSP-1 are currently lacking. Materials and methods: In this study, immunohistochemistry was performed to elucidate the invivo relationships between Her-2/. neu and TSP-1 expression, angiogenesis, and lymphangiogenesis in breast cancer. Based on immunohistochemical staining for anti-Her-2/. neu and related quantitative scoring of tumor cells, 28 individuals with high Her-2/. Neu expression (i.e., with a score of ≥2.0) were recruited into the study group. Another 28 individuals with low Her-2/. neu (i.e., with a score of ",

keywords = "Angiogenesis, Automated cellular imaging system, Breast cancer, Her-2/neu, Lymphangiogenesis, Thrombospondin-1, Tumor-stroma interaction",

author = "Hong, {Ming Chuan} and Long, {Cheng Yu} and Tian, {Yu Feng} and Wu, {Ming Ping}",

note = "Funding Information: We thank Dr. Cheng C Tsai for his kind technical support and for the cooperation of his colleagues Mr. Matthew J Morgan and Miss Cindy Kilpack of WCP Pathology Laboratories, Inc. We thank Miss Chin-Li Lu for her assistance with the statistics analysis, and Miss Shao-Kuan Phyllis Hsu for medical English editing (Department of Medical Research, Chi Mei Foundation Hospital, Tainan, Taiwan). We acknowledge receipt of grant support to Ming-Ping Wu from the National Science Council Taiwan for Ph.D. Student Study Abroad Program (Grant No. 93-2917-I-006-002 ).",

year = "2013",

month = nov,

doi = "10.1016/j.gmit.2013.07.001",

language = "English",

volume = "2",

pages = "114--121",

journal = "Gynecology and Minimally Invasive Therapy",

issn = "2213-3070",

publisher = "Wolters Kluwer Medknow Publications",

number = "4",

}

TY - JOUR

T1 - Her-2/neu overexpression is associated with thrombospondin-1-related angiogenesis and thrombospondin-1-unrelated lymphangiogenesis in breast cancer

AU - Hong, Ming Chuan

AU - Long, Cheng Yu

AU - Tian, Yu Feng

AU - Wu, Ming Ping

N1 - Funding Information: We thank Dr. Cheng C Tsai for his kind technical support and for the cooperation of his colleagues Mr. Matthew J Morgan and Miss Cindy Kilpack of WCP Pathology Laboratories, Inc. We thank Miss Chin-Li Lu for her assistance with the statistics analysis, and Miss Shao-Kuan Phyllis Hsu for medical English editing (Department of Medical Research, Chi Mei Foundation Hospital, Tainan, Taiwan). We acknowledge receipt of grant support to Ming-Ping Wu from the National Science Council Taiwan for Ph.D. Student Study Abroad Program (Grant No. 93-2917-I-006-002 ).

PY - 2013/11

Y1 - 2013/11

N2 - Introduction: Her-2/. neu overexpression is linked to poor prognosis and is a significant predictor of the response to trastuzumab (i.e., herceptin) therapy in breast cancer patients. Her-2/. neu promotes angiogenesis with thrombospondin-1 (TSP-1) as a mediator in breast cancer development and progression. However, the clinical quantitative evaluation of Her-2/. neu and specified localization of TSP-1 are currently lacking. Materials and methods: In this study, immunohistochemistry was performed to elucidate the invivo relationships between Her-2/. neu and TSP-1 expression, angiogenesis, and lymphangiogenesis in breast cancer. Based on immunohistochemical staining for anti-Her-2/. neu and related quantitative scoring of tumor cells, 28 individuals with high Her-2/. Neu expression (i.e., with a score of ≥2.0) were recruited into the study group. Another 28 individuals with low Her-2/. neu (i.e., with a score of

AB - Introduction: Her-2/. neu overexpression is linked to poor prognosis and is a significant predictor of the response to trastuzumab (i.e., herceptin) therapy in breast cancer patients. Her-2/. neu promotes angiogenesis with thrombospondin-1 (TSP-1) as a mediator in breast cancer development and progression. However, the clinical quantitative evaluation of Her-2/. neu and specified localization of TSP-1 are currently lacking. Materials and methods: In this study, immunohistochemistry was performed to elucidate the invivo relationships between Her-2/. neu and TSP-1 expression, angiogenesis, and lymphangiogenesis in breast cancer. Based on immunohistochemical staining for anti-Her-2/. neu and related quantitative scoring of tumor cells, 28 individuals with high Her-2/. Neu expression (i.e., with a score of ≥2.0) were recruited into the study group. Another 28 individuals with low Her-2/. neu (i.e., with a score of

KW - Angiogenesis

KW - Automated cellular imaging system

KW - Breast cancer

KW - Her-2/neu

KW - Lymphangiogenesis

KW - Thrombospondin-1

KW - Tumor-stroma interaction

UR - http://www.scopus.com/inward/record.url?scp=84901740677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901740677&partnerID=8YFLogxK

U2 - 10.1016/j.gmit.2013.07.001

DO - 10.1016/j.gmit.2013.07.001

M3 - Article

AN - SCOPUS:84901740677

SN - 2213-3070

VL - 2

SP - 114

EP - 121

JO - Gynecology and Minimally Invasive Therapy

JF - Gynecology and Minimally Invasive Therapy

IS - 4

ER -

Her-2/neu overexpression is associated with thrombospondin-1-related angiogenesis and thrombospondin-1-unrelated lymphangiogenesis in breast cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this